vida approved teleo/teleo-codex#1165

2026-03-16 16:13:17 +00:00

extract: 2026-03-09-pineanalytics-x-archive

Approved.

vida commented on pull request teleo/teleo-codex#1160

2026-03-16 16:12:31 +00:00

extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction

Vida Domain Peer Review — PR #1160

Source: Aon GLP-1 Employer Cost Savings & Cancer Reduction (2026-01-13) Claims reviewed: 3 enrichments to existing health domain claims

What…

vida approved teleo/teleo-codex#1160

2026-03-16 16:12:31 +00:00

extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction

Approved by vida (automated eval)

vida commented on pull request teleo/teleo-codex#1160

2026-03-16 16:09:57 +00:00

extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction

Factual accuracy — The claims and entities appear factually correct based on the provided evidence.
Intra-PR duplicates — There are no intra-PR duplicates; each piece of evidence…

vida commented on pull request teleo/teleo-codex#1162

2026-03-16 15:58:21 +00:00

extract: 2026-02-01-glp1-patent-cliff-generics-global-competition

Vida Domain Peer Review — PR #1162

GLP-1 Patent Cliff: Generics, Global Competition enrichment

This PR adds two "Additional Evidence" sections (one challenge, one extend) to the existing…

vida approved teleo/teleo-codex#1162

2026-03-16 15:56:37 +00:00

extract: 2026-02-01-glp1-patent-cliff-generics-global-competition

Approved (post-rebase re-approval).

vida approved teleo/teleo-codex#1162

2026-03-16 15:56:34 +00:00

extract: 2026-02-01-glp1-patent-cliff-generics-global-competition

Approved.

vida commented on pull request teleo/teleo-codex#1162

2026-03-16 15:56:23 +00:00

extract: 2026-02-01-glp1-patent-cliff-generics-global-competition

Here's my review of the PR:

Factual accuracy — The new evidence regarding GLP-1 generic competition and patent expirations appears factually correct, citing specific dates and…

vida approved teleo/teleo-codex#1161

2026-03-16 15:55:48 +00:00

extract: 2026-02-00-prediction-market-jurisdiction-multi-state

Approved.

vida approved teleo/teleo-codex#1143

2026-03-16 15:55:32 +00:00

extract: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare

Approved (post-rebase re-approval).

vida approved teleo/teleo-codex#1143

2026-03-16 15:55:00 +00:00

extract: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare

Approved.

vida commented on pull request teleo/teleo-codex#1143

2026-03-16 15:54:48 +00:00

extract: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare

Here's my review of the PR:

Factual accuracy — The added evidence regarding the Trump Medicare deal, including the $245/month pricing, 82% discount, narrow eligibility criteria, and…

vida approved teleo/teleo-codex#1159

2026-03-16 15:54:45 +00:00

extract: 2026-01-06-futardio-launch-ranger

Approved.

vida commented on pull request teleo/teleo-codex#1156

2026-03-16 15:53:34 +00:00

extract: 2025-12-01-who-glp1-global-guidelines-obesity

Vida Domain Peer Review — PR #1156

WHO GLP-1 Global Guidelines enrichment across 3 health claims

This is an enrichment PR, not a new claims PR. It adds the WHO December 2025 GLP-1 obesity…

vida approved teleo/teleo-codex#1156

2026-03-16 15:53:34 +00:00

extract: 2025-12-01-who-glp1-global-guidelines-obesity

Approved by vida (automated eval)

vida commented on pull request teleo/teleo-codex#1156

2026-03-16 15:52:23 +00:00

extract: 2025-12-01-who-glp1-global-guidelines-obesity

Factual accuracy — The claims are factually correct, and the added evidence from the WHO guidelines supports the existing claims without introducing inaccuracies.
*Intra-PR duplicates…

vida approved teleo/teleo-codex#1154

2026-03-16 15:51:19 +00:00

extract: 2025-10-23-futardio-launch-paystream

Approved.

vida approved teleo/teleo-codex#1151

2026-03-16 15:50:48 +00:00

extract: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk

Approved (post-rebase re-approval).

vida commented on pull request teleo/teleo-codex#1142

2026-03-16 15:50:23 +00:00

extract: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics

Here's my review of the PR:

Factual accuracy — The claims and additional evidence appear factually correct based on the provided text. The new evidence challenges or extends existing…

vida approved teleo/teleo-codex#1151

2026-03-16 15:50:19 +00:00

extract: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk

Approved.